Weatherford International has a market cap of $8.68 billion and an enterprise value of $17.10 billion. This stock trades at a cheap valuation, with a forward price-to-earnings of 10.71. Its estimated growth rate for this year is 2.9%, and for next year it's pegged at 47.2%. This is not a cash-rich company, since the total cash position on its balance sheet is $365 million and its total debt is a whopping $8.91 billion.
A vice president just
bought 40,000 shares, or about $423,000 worth of stock, at $10.59 per share.
Another vice president also just
bought 20,000 shares, or about $217,000 worth of stock, at $10.88 per share.
From a technical perspective, WFT is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock has been uptrending strongly for the last month and change, with shares soaring from a low of $8.84 to its recent high of $11.58 a share. During that uptrend, shares of WFT have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed WFT within range of triggering a near-term breakout trade.
If you're bullish on WFT, then I would look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $11.41 to $11.77 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 10.6 million shares. If that breakout hits soon, then WFT will set up to re-test or possibly take out its next major overhead resistance levels at $12.47 to $12.56 a share. Any move above those levels will then put $12.92 to $13.50 into focus for shares of WFT.
One biotechnology and drugs player that insiders are jumping into here is
(ALXA - Get Report)
, which is focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Insiders are buying this stock into modest strength, since shares are up by 10.3% during the last six months.
Alexza Pharmaceuticals has a market cap of $78 million and an enterprise value $60 million. This stock trades at a premium valuation, with a price-to-sales of 14.86 and a price-to-book of 7.57. Its estimated growth rate for this year is 66.7%, and for next year it's pegged at 38%. This is a cash-rich company, since the total cash position on its balance sheet is $25.51 million and its total debt is $7.99 million. After you back out the debt, this company has $17.52 million of total cash on its books.